Insider Buying: EKF Diagnostics Holdings plc (LON:EKF) Insider Acquires 50,000 Shares of Stock

EKF Diagnostics Holdings plc (LON:EKF) insider Gavin T. Jones purchased 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 25th. The shares were purchased at an average cost of GBX 22 ($0.28) per share, with a total value of £11,000 ($14,241.33).

EKF Diagnostics Price Performance

EKF opened at GBX 22.11 ($0.29) on Wednesday. The company’s 50 day simple moving average is GBX 23.30 and its 200-day simple moving average is GBX 25.88. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.60 and a quick ratio of 1.77. The stock has a market capitalization of £98.28 million, a P/E ratio of 20.58 and a beta of 0.57. EKF Diagnostics Holdings plc has a one year low of GBX 18.40 ($0.24) and a one year high of GBX 33.80 ($0.44).

EKF Diagnostics (LON:EKF) last posted its quarterly earnings data on Tuesday, March 25th. The company reported GBX 1.38 ($0.02) EPS for the quarter. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%. Sell-side analysts anticipate that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current fiscal year.

About EKF Diagnostics

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.